Clinical Trial Detail

NCT ID NCT04189614
Title An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors AbbVie
Indications

lung non-small cell carcinoma

Therapies

Cofetuzumab pelidotin

Age Groups: senior adult

No variant requirements are available.